- Trials with a EudraCT protocol (1,169)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,169 result(s) found for: Levels of biomarkers.
Displaying page 6 of 59.
EudraCT Number: 2008-001409-40 | Sponsor Protocol Number: S334.2.002 | Start Date*: 2009-03-04 | |||||||||||
Sponsor Name:Solvay Pharmaceuticals B.V. | |||||||||||||
Full Title: A Randomized, Double blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics after Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients with ... | |||||||||||||
Medical condition: Moderate and severe Traumatic Brain Injury (TBI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003780-21 | Sponsor Protocol Number: RP1907 | Start Date*: 2020-03-31 | |||||||||||
Sponsor Name:Alimentiv Inc. | |||||||||||||
Full Title: Pharmacokinetics and Pharmacodynamic Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis (PROPHETIC Study) | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000894-26 | Sponsor Protocol Number: BN42083 | Start Date*: 2020-10-12 | |||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||
Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPL... | |||||||||||||||||||||||
Medical condition: Primary Progressive Multiple Sclerosis (MS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002762-12 | Sponsor Protocol Number: SJ-674 | Start Date*: 2021-12-07 |
Sponsor Name:Zealand University Hospital | ||
Full Title: The prevalence of bile acid diarrhéa and the effect of budesonid on the bile acid homeostasis in patients with microscopic colitis | ||
Medical condition: Microscopic colitis Bile acid diarrhea | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003896-41 | Sponsor Protocol Number: D5181C00001 | Start Date*: 2015-03-27 | |||||||||||
Sponsor Name:MedImmune, LLC | |||||||||||||
Full Title: A Phase 2a, Randomized, Placebo-controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects with Primary Sjogren’s Syndrome | |||||||||||||
Medical condition: Primary Sjogren’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003836-77 | Sponsor Protocol Number: OCTO-003 | Start Date*: 2008-12-09 |
Sponsor Name:University of Oxford | ||
Full Title: AspECT - A phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia & oesophagitis. | ||
Medical condition: Barrett's Metaplasia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2023-000785-33 | Sponsor Protocol Number: HST20-CL01 | Start Date*: 2023-08-18 |
Sponsor Name:HemoShear Therapeutics | ||
Full Title: A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects with Propionic or Methylmalonic Acidemia Followed by a 6-Month, Randomized, Double-blind, Placebo-controlled, 2-Period Crossover S... | ||
Medical condition: Methylmalonic Acidemia (MMA) Propionic Acidemia (PA) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2006-004245-42 | Sponsor Protocol Number: 10078 | Start Date*: 2006-09-07 | |||||||||||
Sponsor Name:University Hospitals of Leicester NHS Trust | |||||||||||||
Full Title: PHARMACODYNAMIC STUDY OF ORAL MIRTOSELECT IN PATIENTS WITH SUSPECTED HEPATIC DISEASE | |||||||||||||
Medical condition: Patients with operable liver metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001207-68 | Sponsor Protocol Number: KKSH140 | Start Date*: 2018-11-20 | ||||||||||||||||
Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | ||||||||||||||||||
Full Title: A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors | ||||||||||||||||||
Medical condition: Progressive well-differentiated metastatic pancreatic neuroendocrine tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000875-37 | Sponsor Protocol Number: VanC-IT | Start Date*: 2022-11-03 | |||||||||||
Sponsor Name:UNIVERSITÀ DEGLI STUDI MILANO BICOCCA | |||||||||||||
Full Title: A Prospective, Randomized, Placebo-controlled Clinical Trial of oral vancomycin in adults and young adults (15-17 years old) affected by Primary Sclerosing Cholangitis with or without Inflammatory ... | |||||||||||||
Medical condition: Primary Sclerosing Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003288-20 | Sponsor Protocol Number: BN29553 | Start Date*: 2017-05-07 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) EE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) DE (Prematurely Ended) GR (Prematurely Ended) FR (Completed) SE (Prematurely Ended) DK (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011245-55 | Sponsor Protocol Number: 09575704 | Start Date*: 2009-05-06 |
Sponsor Name:Active Biotech Research AB | ||
Full Title: An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE). Final Protocol dated 20... | ||
Medical condition: Systemic Lupus Erythematosus (SLE) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002523-14 | Sponsor Protocol Number: A536-03 | Start Date*: 2012-12-20 | ||||||||||||||||
Sponsor Name:Acceleron Pharma Inc. | ||||||||||||||||||
Full Title: A Phase 2, Open-Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | ||||||||||||||||||
Medical condition: Myelodysplastic Syndromes (MDS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004228-37 | Sponsor Protocol Number: TransValid-KFO179/GRCSG-B | Start Date*: 2012-10-16 |
Sponsor Name:Universitätsmedizin Goettingen | ||
Full Title: Translational Validation Trial-B (add-on phase I/II study to the Clinical Research Unit (Klinische Forschergruppe) KFO179-2 | ||
Medical condition: Patients with advanced but resectable rectal cancer (clinically staged as rectal cancers of the UICC stages II, III or IV) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004824-77 | Sponsor Protocol Number: 27UCS2015 | Start Date*: 2016-06-23 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial design biomarker tertiary prevention trial of low-dose aspirin and metformin in resected stage I-III colorectal ... | |||||||||||||
Medical condition: Surgical resected colorectal cancer (stage I-III) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004149-17 | Sponsor Protocol Number: 40346527ALZ1001 | Start Date*: 2019-06-07 | |||||||||||
Sponsor Name:University of Oxford / Clinical Trials and Research Governance | |||||||||||||
Full Title: A randomised, placebo-controlled, single-blind study to characterise the biomarker effects of the CSF-1 receptor antagonist JNJ-40346527 in participants with mild cognitive impairment | |||||||||||||
Medical condition: Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001236-10 | Sponsor Protocol Number: COVID-19 | Start Date*: 2020-03-31 |
Sponsor Name:Amsterdam UMC | ||
Full Title: COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in Covid19 – a randomized, double --blind, placebo controlled, clinical trial in patients with severe Covid19 disease’ | ||
Medical condition: Covid19 is characterized by hypoxemic respiratory failure, caused by extensive vascular leak and pulmonary edema early in the course of disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001802-30 | Sponsor Protocol Number: TMP-3001-2020-30 | Start Date*: 2021-10-28 |
Sponsor Name:Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP) | ||
Full Title: Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus (BeCarma) | ||
Medical condition: Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006562-20 | Sponsor Protocol Number: JAKIPRA | Start Date*: 2022-10-26 | |||||||||||
Sponsor Name:Universitätsklinikum Erlangen | |||||||||||||
Full Title: JAK Inhibition in PReclinical Arthritis | |||||||||||||
Medical condition: Preclinical Phase of rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004239-35 | Sponsor Protocol Number: 2017/16 | Start Date*: 2019-09-26 | |||||||||||
Sponsor Name:Centre Antoine Lacassagne | |||||||||||||
Full Title: Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas | |||||||||||||
Medical condition: Soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
